New Parkinson’s Disease Research Maps Out Inhibitory Processes

Neurotransmission pic


As CEO of Consonance Capital, Dr. Mitchell Blutt guides private equity funds and health care investments. Community focused, Dr. Mitchell Blutt supports a number of nonprofits and is a past board member of the Michael J. Fox Foundation, which is working to find a cure for Parkinson’s disease.

Impacting 10 million people across the globe, Parkinson’s disease is a neurological condition that results in deterioration of physical function, with uncontrollable tremors leading to nerve cells misfiring and dying within the brain. Still incurable, Parkinson’s disease is not fully understood by medical researchers.

A recently published study by the Okinawa Institute of Science and Technology Graduate University revealed the protein that blocks the proper transmission of neural signals that underpin higher brain functioning. Neurotransmission enables neurons to communicate signals effectively and transfer them in ways that allow seamless sensory motor functioning.

The chemical messengers contained in vesicle endocytosis within the nerve terminal are essential in transmitting neurological signals. When the process of endocytosis is inhibited during times of heavy use, processes breakdown and sensory perception of motor control is affected. Understanding this inhibitory process promises to offer a vital step toward tailoring treatments to actual neurological conditions in ways that have a positive for among patients.


Urban Health Research at the New York Academy of Medicine

Institute for Urban Health pic

Institute for Urban Health

A health care executive based in New York City, Dr. Mitchell Blutt serves as the chief executive officer of Consonance Capital. Dr. Mitchell Blutt is also a member of the New York Academy of Medicine, a nonprofit organization dedicated to improving the overall health of people living in urban settings.

The New York Academy of Medicine hosts the Institute for Urban Health, a policy organization designed to create innovative solutions to health issues in cities. The Institute for Urban Health takes a collaborative, interdisciplinary approach to improving urban health. In particular, the Institute focuses on matters such as increasing preventive care and healthy aging and eliminating health disparities.

To accomplish its mission, the Institute for Urban Health conducts a variety of studies using quantitative and qualitative research. The organization partners chiefly with health care systems and health departments across New York City, as well as local universities and community organizations. The Institute for Urban Health performs its research through units such as the Center for Health Innovation, which focuses on the most important determinants of health on a broad scale.

Michael J. Fox Foundation Expands its Biomarker Clinical Study

As the founder and CEO of New York-based Consonance Capital, Mitchell Blutt manages the healthcare investment firm’s hedge funds and private equity funds. A philanthropic individual, Mitchell Blutt served as a board member of the Michael J. Fox Foundation, which helps those affected by Parkinson’s disease. Established in 2000, the Foundation is the largest non-profit organization focusing on Parkinson’s disease, and has raised more than $350 million.

In 2010, the foundation created a five-year biomarker clinical study, entitled the Parkinson’s Progression Markers Initiative (PPMI), to study the imaging, clinical, and biological data associated with the disease. The foundation dedicated $45 million to this endeavor and recruited individuals to participate in the trial. In February 2014, the foundation announced that it is seeking additional participants who possess genetic mutations associated with the disease. The overall goal is to make a connection between the onset of the disease and having the gene LRRK2 mutation. This gene is the most common genetic contributor to the disease. Those who meet the qualifications may receive genetic counseling through the PPMI and the Foundation.